Exploring how microbiome signatures change across inflammatory bowel disease conditions and disease locations

Abstract Understanding the variables that influence microbiome studies is critical for successful translational research. Inflammatory bowel disease (IBD) is a complex group of diseases that can present at multiple locations within the Gastrointestinal tract. Here, using the FAMISHED study cohort, w...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Gregory C. A. Amos, Chrysi Sergaki, Alastair Logan, Rolland Iriarte, Ayman Bannaga, Subashini Chandrapalan, Elizabeth M. H. Wellington, Sjoerd Rijpkema, Ramesh P. Arasaradnam
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/3a02788134764d06accd5d2975c7db27
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3a02788134764d06accd5d2975c7db27
record_format	dspace
spelling	oai:doaj.org-article:3a02788134764d06accd5d2975c7db272021-12-02T18:13:45ZExploring how microbiome signatures change across inflammatory bowel disease conditions and disease locations10.1038/s41598-021-96942-z2045-2322https://doaj.org/article/3a02788134764d06accd5d2975c7db272021-09-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-96942-zhttps://doaj.org/toc/2045-2322Abstract Understanding the variables that influence microbiome studies is critical for successful translational research. Inflammatory bowel disease (IBD) is a complex group of diseases that can present at multiple locations within the Gastrointestinal tract. Here, using the FAMISHED study cohort, we aimed to investigate the relationship between IBD condition, IBD disease location, and the microbiome. Signatures of the microbiome, including measures of diversity, taxonomy, and functionality, all significantly differed across the three different IBD conditions, Crohn’s disease (CD), ulcerative colitis (UC), and microscopic colitis (MC). Notably, when stratifying by disease location, patients with CD in the terminal ileum were more similar to healthy controls than patients with CD in the small bowel or colon, however no differences were observed at different disease locations across patients with UC. Change in taxonomic composition resulted in changes in function, with CD at each disease location, UC and MC all having unique functional dysbioses. CD patients in particular had deficiencies in Short-Chain Fatty Acid (SCFA) pathways. Our results demonstrate the complex relationship between IBD and the microbiome and highlight the need for consistent strategies for the stratification of clinical cohorts and downstream analysis to ensure results across microbiome studies and clinical trials are comparable.Gregory C. A. AmosChrysi SergakiAlastair LoganRolland IriarteAyman BannagaSubashini ChandrapalanElizabeth M. H. WellingtonSjoerd RijpkemaRamesh P. ArasaradnamNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Gregory C. A. Amos Chrysi Sergaki Alastair Logan Rolland Iriarte Ayman Bannaga Subashini Chandrapalan Elizabeth M. H. Wellington Sjoerd Rijpkema Ramesh P. Arasaradnam Exploring how microbiome signatures change across inflammatory bowel disease conditions and disease locations
description	Abstract Understanding the variables that influence microbiome studies is critical for successful translational research. Inflammatory bowel disease (IBD) is a complex group of diseases that can present at multiple locations within the Gastrointestinal tract. Here, using the FAMISHED study cohort, we aimed to investigate the relationship between IBD condition, IBD disease location, and the microbiome. Signatures of the microbiome, including measures of diversity, taxonomy, and functionality, all significantly differed across the three different IBD conditions, Crohn’s disease (CD), ulcerative colitis (UC), and microscopic colitis (MC). Notably, when stratifying by disease location, patients with CD in the terminal ileum were more similar to healthy controls than patients with CD in the small bowel or colon, however no differences were observed at different disease locations across patients with UC. Change in taxonomic composition resulted in changes in function, with CD at each disease location, UC and MC all having unique functional dysbioses. CD patients in particular had deficiencies in Short-Chain Fatty Acid (SCFA) pathways. Our results demonstrate the complex relationship between IBD and the microbiome and highlight the need for consistent strategies for the stratification of clinical cohorts and downstream analysis to ensure results across microbiome studies and clinical trials are comparable.
format	article
author	Gregory C. A. Amos Chrysi Sergaki Alastair Logan Rolland Iriarte Ayman Bannaga Subashini Chandrapalan Elizabeth M. H. Wellington Sjoerd Rijpkema Ramesh P. Arasaradnam
author_facet	Gregory C. A. Amos Chrysi Sergaki Alastair Logan Rolland Iriarte Ayman Bannaga Subashini Chandrapalan Elizabeth M. H. Wellington Sjoerd Rijpkema Ramesh P. Arasaradnam
author_sort	Gregory C. A. Amos
title	Exploring how microbiome signatures change across inflammatory bowel disease conditions and disease locations
title_short	Exploring how microbiome signatures change across inflammatory bowel disease conditions and disease locations
title_full	Exploring how microbiome signatures change across inflammatory bowel disease conditions and disease locations
title_fullStr	Exploring how microbiome signatures change across inflammatory bowel disease conditions and disease locations
title_full_unstemmed	Exploring how microbiome signatures change across inflammatory bowel disease conditions and disease locations
title_sort	exploring how microbiome signatures change across inflammatory bowel disease conditions and disease locations
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/3a02788134764d06accd5d2975c7db27
work_keys_str_mv	AT gregorycaamos exploringhowmicrobiomesignatureschangeacrossinflammatoryboweldiseaseconditionsanddiseaselocations AT chrysisergaki exploringhowmicrobiomesignatureschangeacrossinflammatoryboweldiseaseconditionsanddiseaselocations AT alastairlogan exploringhowmicrobiomesignatureschangeacrossinflammatoryboweldiseaseconditionsanddiseaselocations AT rollandiriarte exploringhowmicrobiomesignatureschangeacrossinflammatoryboweldiseaseconditionsanddiseaselocations AT aymanbannaga exploringhowmicrobiomesignatureschangeacrossinflammatoryboweldiseaseconditionsanddiseaselocations AT subashinichandrapalan exploringhowmicrobiomesignatureschangeacrossinflammatoryboweldiseaseconditionsanddiseaselocations AT elizabethmhwellington exploringhowmicrobiomesignatureschangeacrossinflammatoryboweldiseaseconditionsanddiseaselocations AT sjoerdrijpkema exploringhowmicrobiomesignatureschangeacrossinflammatoryboweldiseaseconditionsanddiseaselocations AT rameshparasaradnam exploringhowmicrobiomesignatureschangeacrossinflammatoryboweldiseaseconditionsanddiseaselocations
_version_	1718378446179008512

Exploring how microbiome signatures change across inflammatory bowel disease conditions and disease locations

Ejemplares similares